Clinical Evaluation of Glucocorticoid Combined with Leflunomide in the Treatment forPatientswith IgA Nephropathy
CAO Kun, WANG Zhen
2022, 40(12):
1-4.
Asbtract
(
181 )
PDF (2116KB)
(
26
)
References |
Related Articles |
Metrics
Objective To study the clinical effect of glucocorticoid combined with leflunomide on patients with IgA nephropathy. Methods A total of 100 patients with IgA nephropathy admitted to Pingyi County People’s Hospital were divided into 50 cases in each group by drawing lots from January 2020 to January 2021. The routine group was treated with prednisone, while the experimental group was treated with glucocorticoid combined with leflunomide. 24-hour urine protein quantity, serum myotoxicity, systolic blood pressure, diastolic blood pressure, glomerular filtration rate (GFR), urinary vascular cell adhesion molecule-1 (VCAM-1), Toll-like receptor-9 protein (TLR-9) were observed and compared; Treatment effect, clinical symptoms and other indicators were also evaluated and compared. Results After treatment, the indexes of the two groups were improved,with significant differences(P<0.05), and the 24-hour urinary protein quantity, systolic blood pressure, diastolic blood pressure, GFR, VCAM-1, TLR-9 group were significantly different in the experimental group(P<0.05). The average hospitalization time, symptom improvement time and symptom disappearance time of the experimental group were significantly shorter than those of the conventional group, and the difference was statistically significant (P<0.05). The effective rate of the experimental group was higher than that of the control group, and the difference was statistically significant (P<0.05). Conclusion Glucocorticoid combined with leflunomide in the treatment of patients with IgA nephropathy has achieved good results, which is helpful to improve the 24-hour urinary protein and plasma albumin, shorten the treatment time and improve the cure rate, which is worthy of clinical application.